How to accelerate large scale vaccine manufacturing
Vaccine development is a complex and time-consuming process. Finding a candidate that is both safe and effective in triggering an immune response can take many years.
Viruses can also mutate quickly, necessitating new treatments for each new strain.
On demonstration of safety and efficacy, producing sufficient doses for widespread distribution is a further challenge. Biotherapeutics require tightly controlled conditions for production, and it is difficult to maintain these specific conditions when scaling up from a research lab to global production, as needed for a pandemic such as a coronavirus COVID-19. There is also the added time pressure of scaling up a vaccine production as quickly as possible.
Vaccines must be produced in large batches, at a low cost per dose, to offer broad and effective protection. The link between researchers and the vaccine manufacturing process has never been so important. When time is short, process design engineers and researchers need to work together to ensure that the vaccine can be replicated reliably at scale for clinical trials and then again at an even greater scale for mass production.
As a fluid path partner to bioprocessing companies worldwide, we form a link between research and development teams, and process engineers to ensure the optimum equipment performance throughout each development stage. As development reaches production, your processing equipment, materials, and processes must be validated and deliver safe, consistent viability and product quality. Leveraging our entire fluid path portfolio supports a reduction in additional validation steps, accelerating the progression from bench to production.
Please explore our complete fluid path portfolio
We are continuously innovating to help support advancements in process intensification. Through our single-use technologies, including high-purity tubing optimised for our leading peristaltic pumps, we offer engineering support.
For example, our Quantum technology, developed specifically for downstream processing, meets the industries need to make downstream steps such as harvest transfer, ultra/diafiltration feeds, and chromatography more efficient.
From drug discovery to biomanufacturing, choosing our validated and reliable processing technology means we can support the acceleration and simplification of your vaccine development pipeline.
Our vaccine product portfolio
Cobra Biologics and Watson-Marlow Fluid Technology Group discuss the challenges of vaccine production
Join our webinar to hear from Cobra Biologics’ Technical Director, Tony Hitchcock, and from Watson-Marlow Fluid Technology Group’s (WMFTG) Peter Birch and Dr Sade Mokuolu, as they discuss the strategies for vaccine production, whilst maintaining critical quality standards.
This webinar will discuss:
- The vaccines research landscape
- Learnings from previous epidemics including Ebola, SARS and MERS
- Progress made so far in the COVID-19 pandemic
- The challenges of vaccine development including the skills, technology and resources needed
- A particular focus on the challenges of scaling up production for a global pandemic
Friday, 25 September 2020